. 2018 Mar 8;9(1):13–20. doi: 10.14740/wjon1084w

Table 2. Treatment and Efficacy.

	All, N = 159	LMR			mGPS
	All, N = 159	< 1.97, N = 24	≥ 1.97, N = 135	P	0 - 1, N = 120	2, N = 39	P
First-line regimen
Single or combination (N)
Single/combination	4/155	0/24	4/131	1.00^a	4/116	0/39	0.57^a
Platinum-based (N)
CDDP/CBDCA	52/103	8/16	44/87	1.00^a	43/73	9/30	0.12^a
PEM-containing (N)	77	13	64	0.66^a	59	18	0.85^a
Bev-containing (N)	32	4	28	0.79^a	23	9	0.65^a
Concurrent TRT (N)	8	0	8	0.61^a	6	2	1.00^a
First-line response
RR (%) (95% CI)	40.9 (33.2 - 48.9)	8.3 (1.0 - 27.0)	46.7 (38.0 - 55.4)	< 0.01^a	45.0 (35.9 - 54.3)	28.2 (15.0 - 44.9)	0.09^a
DCR (%) (95% CI)	69.8 (62.0 - 76.8)	33.3 (15.6 - 55.3)	76.3 (68.2 - 83.2)	< 0.01^a	76.7 (68.1 - 83.9)	48.7 (32.4 - 65.2)	< 0.01^a
PFS (months) (95% CI)	5.4 (4.6 - 6.3)	2.7 (1.0 - 3.7)	5.7 (5.3 - 6.6)	< 0.01^b	5.7 (5.2 - 6.8)	3.1 (1.6 - 5.3)	0.01^b
Second or further line (N)	96	5	91	< 0.01^a	84	12	< 0.01^a
ICI (N)	20	1	19	0.31^a	18	2	0.16^a

^aFisher’s exact test. ^bLog-rank test. Bev: bevacizumab; CBDCA: carboplatin; CDDP: cisplatin; CI: confidence interval; DCR: disease control rate; ICI: immuno-checkpoint inhibitor; LMR: lymphocyte to monocyte ratio; mGPS: modified Glasgow prognostic score; PEM: pemetrexed; PFS: progression-free survival; RR: response rate; TRT: thoracic radiotherapy.